Cukierman-Yaffe, T., Gerstein, H. C., Colhoun, H. M., Diaz, R., García-Pérez, L., Lakshmanan, M., Bethel, A., Xavier, D., Probstfield, J., Riddle, M. C., Rydén, L., Atisso, C. M., Hall, S., Rao-Melacini, P., Basile, J., Cushman, W. C., Franek, E., Keltai, M., Lanas, F., Leiter, L. A., Lopez-Jaramillo, P., Pirags, V., Pogosova, N., Raubenheimer, P. J., Shaw, J. E., Sheu, W. H., & Temelkova-Kurktschiev, T. (2020). effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. Lancet neurology, 19(7), 582–590. http://access.bl.uk/ark:/81055/vdc_100104104267.0x000015